L-Carnitine (200 mg Vial)
L-Carnitine is an amino acid derivative essential for fatty acid transport into mitochondria, where it facilitates β-oxidation and energy production. Subcutaneous administration bypasses intestinal conversion to trimethylamine-N-oxide (TMAO), a metabolite associated with cardiovascular concerns, while providing 100% bioavailability compared to 5–18% for large oral doses. This educational protocol presents a once-daily subcutaneous approach optimized for insulin-syringe measurements.
Detailed protocol below.
| Week | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 50 mg | 50 units (0.50 mL) |
| Weeks 3–8 | 100 mg | 100 units (1.0 mL) |
| Weeks 9–12 | 100 mg | 100 units (1.0 mL) |
- •Peptide Vials (L-Carnitine, 200 mg each):
- •Insulin Syringes (U-100, 1 mL capacity):
- •Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- •Alcohol Swabs: One for vial stopper + one for injection site each day.
- •Sharps Container: For safe disposal of used syringes and needles.
Journal of the International Society of Sports Nutrition (2020)
Sawicka AK et al. The bright and the dark sides of L-carnitine supplementation: a systematic review (dose ranges, mechanisms, and metabolic effects)
View sourceClinical Nutrition ESPEN (2020)
Talenezhad N et al. Meta-analysis of 37 RCTs: L-carnitine supplementation yields ~1.2 kg weight loss at ~2,000 mg/day oral dosing with diminishing returns above that dose (PMID: 32359762)
View sourceClinical Pharmacokinetics (2003)
Evans AM & Fornasini G. Pharmacokinetics of L-carnitine: oral bioavailability only 5–18% at high doses (1–6 g) vs. much higher absorption from IV/parenteral routes (PMID: 12908852)
View sourceMolecular Nutrition & Food Research (2018)
Zhao Y et al. Subcutaneous L-carnitine bypasses gut bacterial TMAO production and does not promote atherosclerosis in ApoE−/− mice, unlike oral dosing (PMID: 29178259)
View sourceAmerican Journal of Kidney Diseases (2001)
Brass EP et al. IV L-carnitine (10–40 mg/kg after dialysis, 3×/week for 24 weeks) increased plasma carnitine, reduced fatigue, preserved exercise capacity in hemodialysis patients with excellent safety profile (PMID: 11325685)
View sourceAdvances in Therapy (2019)
Usach I et al. Subcutaneous injection review: volumes <0.8 mL minimize pain; room-temperature solutions, benzyl alcohol (vs. m-cresol) reduce pain; abdomen preferred site (PMID: 31529256)
View sourceCDC Pink Book (14th Edition)
Vaccine Administration (Chapter 6): subcutaneous injection technique (45–90° angle, no aspiration needed, site selection/rotation)
View sourceDrugs.com (2024)
Levocarnitine (Carnitor) dosing: 50 mg/kg IV daily for metabolic disorders; 10–20 mg/kg IV after dialysis for ESRD; doses up to 300 mg/kg/day used safely (medically reviewed Apr 23, 2024)
View sourceNIH Office of Dietary Supplements (2022)
Carnitine Health Professional Fact Sheet: high oral doses (>3 g/day) cause fishy odor, nausea; unabsorbed carnitine → gut bacterial TMAO production (potential CV risk)
View sourceLinus Pauling Institute, Oregon State University (2022)
L-Carnitine Micronutrient Information Center: FDA-approved uses (dialysis 10–20 mg/kg IV), research summary, safety overview
View sourceCDC Vaccine Administration Guidelines
Best practices during vaccination: subcutaneous injection angle (45–90°), site selection, no aspiration needed, rotation to prevent lipohypertrophy
View sourceNCBI Bookshelf
Clinical Procedures: Best Practices in Injection Administration (aseptic technique, preparation, sharps disposal)
View sourceSB Peptide
Peptide Handling & Storage Guidelines: lyophilized peptides stable for months–years at −20 °C; reconstituted solutions stable 1–2 weeks at 4 °C, longer if frozen in aliquots; avoid freeze–thaw cycles
View source
Educational content adapted from peptidedosages.com. Not medical advice.